faricimab治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿的成本效果分析数据集

数据集获取（Figshare）

• 源站标题：Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan
• DOI：10.6084/m9.figshare.28588419.v2
• 发布日期：2025-03-24
• 文件数：2 个
• 文件总体积：605.45 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_bispecific_antibody_faricimab_for_treatment_of_neovascular_age-related_macular_degeneration_and_diabetic_macular_edema_in_Japan/28588419

命令行下载

curl -L -o "ijme_a_2478755_sm5486.docx" "https://ndownloader.figshare.com/files/53167770"
curl -L -o "ijme_a_2478755_sm0773.docx" "https://ndownloader.figshare.com/files/52964580"

文件清单

• ijme_a_2478755_sm5486.docx（580.32 KB）
• ijme_a_2478755_sm0773.docx（25.12 KB）

文件总体积 605.45 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment.
A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). Further to treatment costs (public payer perspective), the societal burden (societal perspective), including costs of travel, informal care, and productivity, was assessed.
In treatment of nAMD, lifetime quality-adjusted life years (QALYs) gained were highest with faricimab (faricimab T&E: 6.92, ranibizumab PRN: 6.88, ranibizumab T&E: 6.91, aflibercept T&E: 6.89, brolucizumab T&E: 6.89, BSC: 5.99). From the public payer perspective, the lifetime total cost for faricimab T&E was lower than those for ranibizumab (PRN, T&E) and brolucizumab (T&E), comparable to aflibercept T&E, and higher than BSC (incremental costs: 158,385 and 6,475,511 JPY, respectively). As a result, faricimab was cost-effective or dominant in the treatment of nAMD, excluding BSC. From the societal perspective, faricimab was dominant against all comparators in nAMD. In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.
When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.28588419.v2（source: https://tandf.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_bispecific_antibody_faricimab_for_treatment_of_neovascular_age-related_macular_degeneration_and_diabetic_macular_edema_in_Japan/28588419）。